← Back to patent-cliff list
Roginolisib
Tier C — Watch / tradeRoginolisib
Ionctura Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PI3Kδ
Indications (approved)：Chronic lymphocytic leukaemia, Myelofibrosis, Peripheral T-cell lymphoma, Non-small cell lung cancer, Leukaemia, 葡萄膜黑素瘤, Solid tumour, Haematological malignancy
Regional status
US
Phase II
2025-03-19
EU
Phase II
2025-02-27
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Roginolisib?
Approved indications include: Chronic lymphocytic leukaemia, Myelofibrosis, Peripheral T-cell lymphoma, Non-small cell lung cancer, Leukaemia, 葡萄膜黑素瘤, Solid tumour, Haematological malignancy.
When does the Roginolisib patent expire?
No public expiry year is available for Roginolisib yet; this page updates once verified.
How do I get a quote for Roginolisib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01